CD274 and non-small cell lung carcinoma: First-line monotherapy for advanced/metastatic NSCLC with high PD-L1 expression (TPS ≥ 50%); pembrolizumab plus platinum-based chemotherapy for advanced non-squamous NSCLC regardless of PD-L1 status